Febuxostat is a potent, non-purine selective xanthine oxidase inhibitor used for the long-term management of chronic hyperuricemia in patients with gout. To ensure therapeutic efficacy and regulatory compliance,… Read more




![Chemical structure of Methyl 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F923942-34-1-Methyl-2-3-Cyano-4-2-methylpropoxyphenyl-4-methylthiazole-5-carboxylate.png&w=3840&q=75)


Febuxostat is a potent, non-purine selective xanthine oxidase inhibitor used for the long-term management of chronic hyperuricemia in patients with gout. To ensure therapeutic efficacy and regulatory compliance, pharmaceutical laboratories require high-quality reference standards of the active pharmaceutical ingredient, alongside its related process-related impurities, degradation products, and metabolites. These materials are essential for robust impurity profiling and analytical method validation, enabling accurate detection and quantification during manufacturing and stability testing. Additionally, stable isotope labelled versions of Febuxostat provide critical internal standards for mass spectrometry-based assays, such as LC-MS/MS, facilitating precise pharmacokinetic and bioanalytical studies. By utilizing these characterized reference standards, laboratories can maintain rigorous quality control, support genotoxicity assessments, and ensure the safety of the pharmaceutical product throughout its lifecycle.